5-(but-3-ynyl)-3-(2-(trifluoromethoxy)phenyl)-1,2,4-oxadiazole | 872362-84-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 5-(but-3-ynyl)-3-(2-(trifluoromethoxy)phenyl)-1,2,4-oxadiazole
• 英文别名: 5-But-3-ynyl-3-[2-(trifluoromethoxy)phenyl]-1,2,4-oxadiazole
• CAS: 872362-84-0
• 化学式: C₁₃H₉F₃N₂O₂
• 分子量: 282.222
• InChiKey: FCQPHLKNBQHYBC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  20
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.23
• 拓扑面积：
  48.2
• 氢给体数：
  0
• 氢受体数：
  7

文献信息

• NOVEL ALKYNYL DERIVATIVES AS MODULATORS OF METATROPIC GLUTAMATE RECEPTORS
  申请人：Bessis Anne-Sophie

  公开号：US20090124625A1

  公开（公告）日：2009-05-14

  The present invention relates to novel compounds of formula (I) wherein W, n, X and W′ are defined in the description; invention compounds are modulators of metabotropic glutamate receptors—subtype 5 (“mGluR5”) which are useful for the treatment of central nervous system disorders as well as other disorders modulated by mGluR5 receptors.

  本发明涉及化合物的新型配方（I），其中W，n，X和W′在说明书中定义；发明的化合物是代谢型谷氨酸受体-亚型5（“mGluR5”）的调节剂，可用于治疗中枢神经系统疾病以及其他受mGluR5受体调节的疾病。
• NOVEL ALKYNYL DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS
  申请人：Bessis Anne-Sophie

  公开号：US20120277237A1

  公开（公告）日：2012-11-01

  The present invention relates to novel compounds of formula I wherein W, n, X and W′ are defined in the description; invention compounds are modulators of metabotropic glutamate receptors—subtype 5 (“mGluR5”) which are useful for the treatment of central nervous system disorders as well as other disorders modulated by mGluR5 receptors.

  本发明涉及一种新型化合物，其化学式为I，其中W、n、X和W′在说明中有定义；发明化合物是代谢型谷氨酸受体-亚型5（“mGluR5”）的调节剂，可用于治疗中枢神经系统疾病以及其他受mGluR5受体调节的疾病。
• Alkynyl derivatives as modulators of metabotropic glutamate receptors
  申请人：Addex Pharma SA

  公开号：EP2426115A2

  公开（公告）日：2012-03-07

  The present invention relates to novel compounds of formula I wherein W, n, X and W' are defined in the description; invention compounds are modulators of metabotropic glutamate receptors - subtype 5 ("mGluR5") which are useful for the treatment of central nervous system disorders as well as other disorders modulated by mGluR5 receptors.

  本发明涉及式 I 的新型化合物，其中 W、n、X 和 W' 在描述中定义；本发明化合物是代谢谷氨酸受体-亚型 5（"mGluR5"）的调节剂，可用于治疗中枢神经系统疾病以及受 mGluR5 受体调节的其他疾病。
• ALKYNYL DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS
  申请人：Addex Pharmaceuticals SA

  公开号：EP1765795A2

  公开（公告）日：2007-03-28
• US8101637B2
  申请人：——

  公开号：US8101637B2

  公开（公告）日：2012-01-24